Pharma News

Global Pruritus Therapeutic Market to Grow at a CAGR of 4.9% by 2021: Research

  • Posted on: 14 August 2017
  • By: admin

 The global pruritus therapeutic market to grow at a CAGR of 4.95% during the period 2017-2021.Global Pruritus Therapeutic Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.


AGTC Files Investigational New Drug Application for the Treatment of X-Linked Retinitis Pigmentosa caused by Mutations in the RPGR Gene

  • Posted on: 14 August 2017
  • By: admin

Applied Genetic Technologies Corporation a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced that it has filed an Investigational New Drug application (IND) with the U.S. Food and Drug Administration to conduct a Phase 1/2 clinical trial of the company's gene therapy product candidate for the treatment of X-linked retinitis pigmentosa (XLRP) caused by mutations in the RPGR gene.


Dr. Rao Vadlamudi has been elected as President of Commonwealth Pharmacists Association

  • Posted on: 10 August 2017
  • By: PharmaTutor News

Dr. Rao Vadlamudi, President of Indian Pharmaceutical Association (IPA), has been elected as President of Commonwealth Pharmacists Association (CPA) for the year 2017-19 at CPA Conference held at Hyatt Regency, Sydney, Australia from 28 - 30, July 2017. Dr. Rao Vadlamudi is the second Indian professional to be elected as CPA President after a gap of 30 years.


Anthera announces FDA Orphan Drug Designation for Blisibimod for the treatment of IgA Nephropathy

  • Posted on: 10 August 2017
  • By: PharmaTutor News

Anthera Pharmaceuticals announced that blisibimod has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for the treatment of Immunoglobulin A nephropathy (IgAN).  Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including IgAN, systemic lupus erythematosus, and others.


Manufacturers of the Medical Devices are required to obtain manufacturing license under Drugs and Cosmetic Act

  • Posted on: 10 August 2017
  • By: PharmaTutor News

Manufacturers of the Medical Devices are required to obtain manufacturing license under the provisions of Drugs and Cosmetic (D&C) Act & Rules which is notified by Directorate General of Health Services, Ministry of Health & Family Welfare.


Pharma manufacturers are not concerned to implement Good Manufacturing Practices

  • Posted on: 10 August 2017
  • By: PharmaTutor News

Central Drugs Standard Control Organization (CDSCO) emphasize on GMP and GLP compliance to pharmaceutical manufacturers. But it seems like pharma manufacturers are not serious about implementation of GMP and GLP for their manufacturing plants. Before one year, CDSCO asked manufacturers to carry out an assessment of their units and assign themselves quality ratings but so far Indian pharma manufacturers have not submitted self-inspection reports.


Acalabrutinib granted Breakthrough Therapy Designation by USFDA for the treatment of patients with mantle cell lymphoma

  • Posted on: 4 August 2017
  • By: PharmaTutor News

AstraZeneca and its hematology research and development center of excellence, Acerta Pharma, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for acalabrutinib for the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. Acalabrutinib is an investigational, highly selective, potent Bruton tyrosine kinase (BTK) inhibitor in development for the treatment of multiple B-cell cancers.


Pages